Compare CHCO & RAPP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | CHCO | RAPP |
|---|---|---|
| Founded | 1957 | 2022 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | |
| Sector | Finance | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 1.8B |
| IPO Year | 1995 | 2024 |
| Metric | CHCO | RAPP |
|---|---|---|
| Price | $132.05 | $41.71 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 2 | 6 |
| Target Price | ★ $132.50 | $48.50 |
| AVG Volume (30 Days) | 130.1K | ★ 359.4K |
| Earning Date | 04-23-2026 | 05-08-2026 |
| Dividend Yield | ★ 2.87% | N/A |
| EPS Growth | 13.18 | ★ 24.34 |
| EPS | ★ 2.20 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $5.16 | N/A |
| Revenue Next Year | $3.12 | N/A |
| P/E Ratio | $59.89 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $113.21 | $11.33 |
| 52 Week High | $134.92 | $42.27 |
| Indicator | CHCO | RAPP |
|---|---|---|
| Relative Strength Index (RSI) | 62.35 | 63.58 |
| Support Level | $120.29 | $33.54 |
| Resistance Level | N/A | N/A |
| Average True Range (ATR) | 2.85 | 2.50 |
| MACD | 0.37 | 0.36 |
| Stochastic Oscillator | 71.02 | 78.23 |
City Holding Co is a financial holding company. The company conducts its principal activities through its wholly-owned subsidiary, City National Bank of West Virginia (City National). Through the bank, it provides banking, trust and investment management, and other financial solutions through its network of banking offices located in the states of West Virginia, Virginia, southeastern Ohio, and Kentucky. It offers various products and services such as overdraft facilities, savings accounts, credit cards and debit cards, loans for various purposes, investment advisory, securities brokerage, insurance products, and others. The company's business activities are currently limited to one reportable business segment, which is community banking.
Rapport Therapeutics Inc is a clinical-stage biotechnology company dedicated to the discovery and development of small-molecule precision medicines for patients with neurological or psychiatric disorders. The company's portfolio of programs from its RAP technology platform includes RAP-219, an investigational small molecule being developed as a therapy for focal onset seizures, primary generalized tonic-clonic seizures, and bipolar mania. Additionally, it has two discovery-stage nicotinic acetylcholine receptor (nAChR) programs stemming from its RAP technology platform: one being developed for the treatment of chronic pain, and the second, being developed for the treatment of hearing disorders. Geographically, the company operates in the United States.